Show simple item record

dc.contributor.authorFelip, E
dc.contributor.authorBrunsvig, P
dc.contributor.authorVinolas, N
dc.contributor.authorAix, SP
dc.contributor.authorCosta, EC
dc.contributor.authorGomez, MD
dc.contributor.authorPerez, JMT
dc.contributor.authorArriola, E
dc.contributor.authorCampelo, RG
dc.contributor.authorSpicer, JF
dc.contributor.authorThompson, JR
dc.contributor.authorGranados, ALO
dc.contributor.authorHolt, RJ
dc.contributor.authorLorens, K
dc.contributor.authorLorens, JB
dc.contributor.authorShoaib, M
dc.contributor.authorSiddiqui, A
dc.contributor.authorSchmidt, EV
dc.contributor.authorChisamore, MJ
dc.contributor.authorKrebs, Matthew G
dc.date.accessioned2019-11-19T16:01:04Z
dc.date.available2019-11-19T16:01:04Z
dc.date.issued2019en
dc.identifier.citationFelip E, Brunsvig P, Vinolas N, Aix S, Costa E, Gomez M, et al. A phase II study of bemcentinib (BGB324), a first-in-class highly selective AXL inhibitor, with pembrolizumab in pts with advanced NSCLC: OS for stage I and preliminary stage II efficacy. J Clin Oncol. 2019;37(15).en
dc.identifier.doi10.1200/JCO.2019.37.15_suppl.9098en
dc.identifier.urihttp://hdl.handle.net/10541/622443
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1200/JCO.2019.37.15_suppl.9098en
dc.titleA phase II study of bemcentinib (BGB324), a first-in-class highly selective AXL inhibitor, with pembrolizumab in pts with advanced NSCLC: OS for stage I and preliminary stage II efficacyen
dc.typeMeetings and Proceedingsen
dc.contributor.departmentHospital Universitari Vall d'Hebron, Barcelona, Spainen
dc.identifier.journalJournal of Clinical Oncologyen


This item appears in the following Collection(s)

Show simple item record